Sohar Health vs Superluminal Medicines
Side-by-side comparison of AI visibility scores, market position, and capabilities
Healthcare AI providing insurance eligibility verification in 6 seconds at 96% accuracy; $3.8M from YC and Kindred Capital serving Talkiatry with 8x ROI in behavioral health and telehealth.
About
Sohar Health is a healthcare AI company providing automated insurance eligibility and benefits verification for healthcare providers — delivering verification results in 6 seconds with 96% accuracy through a real-time API that replaces the manual insurance verification calls that consume significant administrative time at medical practices, behavioral health providers, and telehealth companies. The company raised $3.8 million in seed funding led by Kindred Capital and Y Combinator in March 2025, processes 60,000+ monthly eligibility checks, and serves providers including Talkiatry (a major telepsychiatry platform) while delivering 8x ROI for clients within 12 months.
Boston AI GPCR drug discovery with $1.3B Eli Lilly collaboration Aug 2025 for obesity/cardiometabolic; $158M total ($120M RA Capital/Insight/NVIDIA/Lilly Series A Sep 2024) with MC4R obesity program advancing to IND competing with Relay Therapeutics.
About
Superluminal Medicines is a Boston-based biotechnology company — backed with approximately $158 million in total funding including a $33 million seed in 2023 and a $120 million Series A in September 2024 led by RA Capital Management with Insight Partners, NVIDIA's NVentures, and Eli Lilly — developing AI-driven small molecule drugs targeting G protein-coupled receptors (GPCRs), combining artificial intelligence, protein dynamics simulation, and structural biology to discover drugs for 70% of GPCRs that currently remain "undruggable" despite GPCRs representing the target class for approximately 35% of all FDA-approved drugs. In August 2025, Superluminal secured a landmark $1.3 billion collaboration agreement with Eli Lilly to discover small molecule therapeutics for obesity and cardiometabolic diseases, and is advancing its lead internal MC4R agonist program (for obesity treatment) toward IND-enabling studies with human trials expected Q4 2026. Founded in 2022.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.